AstraZeneca turns down Pfizer's "final" takeover bid

05/19/2014 | BBC · Chicago Tribune (tiered subscription model)

AstraZeneca has rejected Pfizer's "final offer" of about $92 per share, saying it "undervalues" the company. Observers speculate that Pfizer may appeal directly to AstraZeneca shareholders, who may be more favorable toward an acquisition than the company's board of directors.

View Full Article in:

BBC · Chicago Tribune (tiered subscription model)

Published in Brief: